When diagnosed with cancer, the typical patient responds
with trepidation, anxiety, and fear. This experience
engenders a bewildering set of questions, including the
cause, treatment options, prognosis, appropriate sources of care,
and affordability. Of paramount importance is ready access to expert
resources with the requisite knowledge and skill. Telemedicine is a
modality of care that addresses all these issues.
In the current oncology clinical trials landscape, many barriers
remain to clinical trial enrollment that affect both the oncologist
and the patient. Among these are trial locations, strict eligibility
requirements, insufficient resources to support appropriate clinical
trial education and screening, as well as patient and provider
attitudes about trials.
As a genitourinary medical oncologist specializing in immunotherapy for kidney and bladder cancers, I am continually striving for more ways to connect with and learn from my patients. The emerging availability of immuno-oncology (IO) drugs for the conditions I treat, as well as many other cancer types, has generated tremendous excitement amongst patients and oncologists, but there still is so much we don’t know.
Teri Bedard, BA, RT(R)(T), CPC, Director, Client Services, Revenue Cycle Coding Strategies LLC discusses CMS’ changes to telehealth coding and billing in response to the COVID-19 public health emergency, includes Q&A. (April 9, 2020)